Tag: Atrial Fibrillation
BMI in Young Males Linked to A-Fib Risk, Outcomes
For those diagnosed with atrial fibrillation, hazard ratios for all-cause mortality, incident heart failure, ischemic stroke increased with higher BMI
Methamphetamines, Opiates, Cocaine, Cannabis Up Risk for A-Fib
Methamphetamine, cocaine, opiate, and cannabis exposure each associated with increased incidence of AF
Apixaban Compared to Rivaroxaban for A-Fib and Valvular Heart Disease
Risks for ischemic stroke or systemic embolism, bleeding reduced with apixaban versus rivaroxaban for atrial fibrillation and valvular heart disease
ECG Anomalies May Affect Accuracy of Smartwatch A-Fib Diagnosis
Nondiagnostic tracings and false positives seen with smartwatch algorithm detection of AF in those with cardiac anomalies
New-Onset A-Fib Profiled in Patients Hospitalized With COVID-19
New-onset atrial fibrillation identified in about one in 20 patients hospitalized with COVID-19
A-Fib Risk Higher in Women After Adjusting for Height, Size
Risk for atrial fibrillation is greater in women than men after adjusting for height, height and weight, or body surface area
Early Rhythm Control May Benefit Low-Risk A-Fib Patients
Early rhythm control linked to reduced risk for cardiovascular complications for those meeting, not meeting eligibility for EAST-AFNET 4 trial
Left Atrial Appendage Occlusion Favored for Some A-Fib Patients
Baseline risks for stroke, bleeding determine whether LAAO is preferred to anticoagulants for a-fib patients with high bleeding risk
Formulary Restrictions May Worsen Atrial Fibrillation Outcomes
Risk for adverse health outcomes higher for patients with Medicare Part D plans limiting access to non-vitamin K antagonist oral anticoagulants
Screening for A-Fib Using Wearable Devices May Be Cost-Effective
Wearable devices are cost-effective compared with no screening or screening using traditional methods
